Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 23INDUSTRY 6NETWORK 4NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Burkitt Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Biphenotypic, Acute 1Down Syndrome 1

Interventions

Cyclophosphamide 385Specimen Handling 371Magnetic Resonance Spectroscopy 325Radiotherapy 306Biopsy 269Cisplatin 257Carboplatin 253Paclitaxel 235Doxorubicin 226Fluorouracil 200Etoposide 197Vincristine 182Bevacizumab 180Filgrastim 170Gemcitabine 163Leucovorin 149Cytarabine 144aldesleukin 140Taxes 127Docetaxel 122Oxaliplatin 113Chemotherapy, Adjuvant 113fludarabine phosphate 111Rituximab 107Methotrexate 107Radiation 106Bortezomib 105Prednisone 102Irinotecan 100Dexamethasone 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Interventional × asparaginase erwinia chrysanthemi recombinant × Clear all
NCT06317662 2026-06-03

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

National Cancer Institute (NCI)

Phase 2 Recruiting
153 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡